Posted by Michael Wonder on 22 Feb 2022
Controversial Alzheimer’s drug under TGA review ‘should not be approved’
21 February 2022 - Patients will be put at risk and taxpayers will face a significant economic burden if aducanumab receives regulatory approval, experts say.
In a Perspective article, published in the Medical Journal of Australia, the authors note that while the drug has received U.S. FDA approval, Phase 3 clinical trials were terminated early after a futility analysis.
